Lysine Trial in Adults With Diarrhoea
NCT02143908 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 440
Last updated 2014-05-21
Summary
Diarrhea as of today is still a major problem in developing world with high morbidity. Though mortality in under-5 children has declined over the years, diarrhea was responsible for 2.5 million deaths per year in developing countries. A median of 3.2 episodes of diarrhea in under-5 children per child-year has been estimated in developing countries. In Bangladesh, the overall prevalence of diarrhea was estimated to be about 2% for the entire population. However, a recent survey in 2003 with urban slum mothers indicated that the prevalence of diarrhea ranged from 0.7-4.1% in six divisional cities with 0.7% in Dhaka slum areas. Malnutrition remains the major adverse prognostic indicator for diarrhea related morbidity, which emphasizes importance of nutrition in early management. Repeated episodes of diarrhea are a frequent cause and consequence of malnutrition. To improve diarrhea situation in Bangladesh and elsewhere, interventions are directed to reduce mortality and morbidity through improvement of breast-feeding practices, complementary feeding, sanitation, increase in measles immunization rates, micronutrient supplementation, and oral rehydration therapy.
L-lysine, an essential amino acid, is required for healthy growth, tissue repair and enzyme production. It is a protein-building block that strengthens and nourishes the structural, circulatory and immune systems. It is not produced by the body like other essential amino acids and must be obtained from the diet. Some natural food sources for L-lysine include Lima beans, kidney beans, potatoes, corn, red meat, fish and milk. The mean requirement of lysine in healthy human adults is about 30 mg/kg body weight/day or 50 mg/g protein intake. Studies have shown that lysine therapy improves immune status and is used as a therapeutic agent in herpes simplex viral infection. A double-blind randomized trial of L-lysine treatment found it to be an effective agent for significant reduction in occurrence, severity and healing time for recurrent herpes simplex viral infection. Lysine fortification increased the blood levels of complement 3 (C3), CD-4 and CD-8 T-cells as compared with controls. These two studies suggest that supplementation of lysine through food fortification enhances immunological status. A few recent studies have also shown an effect of lysine on diarrheal incidence and severity. An experimental model suggested inhibitory effect of L-lysine on incidence of diarrhea induced by stress and 5-hydroxytryptamine. A community trial among adults in Syria showed that the period prevalence and mean duration of diarrheal illness were significantly lower in the female participants who consumed lysine-fortified wheat bread compared to the control group as well as better immunological parameters such as C3c delta.
The proposed study will observe the impact of a daily dose of 2000 mg supplemental L-lysine for 6 months on diarrheal illness in an adult population of an urban slum area in Dhaka whose principal diet is based on cereals such as rice and or wheat. The daily protein and lysine availability from diets of Bangladeshi population has been calculated to be about 43g and 1883 mg respectively, compared to 113g and 7,598 mg respectively in the USA. This means that 2000 mg daily supplementation of L-lysine would not pose any detrimental effect, as the combined usual and supplemental intake will still be substantially lower compared to the intake in USA. However, as expected, the supplemental L-lysine may reduce the incidence and severity of diarrheal illness through improvement of the nutritional and immunological status of the study population.
The investigators propose to conduct a community-based, double-blind randomized controlled trial in Mirpur area of Dhaka city. Adults aged 18 to 45 years residing in the catchment area for at least the last six months will be eligible for the study. A total of 440 subjects (220 females) will be enrolled. The results of the proposed study will contribute to our existing knowledge of the effect of lysine on incidence and severity of diarrheal illness as well as on immune status. A positive impact of lysine supplementation on diarrheal illness may lead to a future strategic approach to the control of diarrhea as a global public health problem.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
lysine supplementation
- DIETARY_SUPPLEMENT
-
Placebo
Sponsors & Collaborators
-
International Centre for Diarrhoeal Disease Research, Bangladesh
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-12-31
- Primary Completion
- 2006-12-31
- Completion
- 2006-12-31
Countries
- Bangladesh
Study Locations
More Related Trials
-
The Effect of Probiotics on E. Coli Gastroenteritis
NCT01225042 ·Status: COMPLETED ·Phase: NA
-
Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial
NCT02871908 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis
NCT01657032 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea
NCT00534170 ·Status: UNKNOWN ·Phase: PHASE3
-
Use of a Dietary Supplement to Support Digestive Health in Children With Chronic Diarrhea
NCT02856386 ·Status: UNKNOWN ·Phase: NA
-
Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile
NCT02127814 ·Status: COMPLETED ·Phase: NA
-
Bacillus Particles Prevent Children Antibiotics Associated Diarrhea
NCT02993419 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders
NCT02722993 ·Status: COMPLETED ·Phase: NA
-
Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection
NCT01087892 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Two Probiotic Preparations in Children With Acute Diarrhoea
NCT02080130 ·Status: WITHDRAWN ·Phase: NA
-
Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children
NCT01564290 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation
NCT02423564 ·Status: COMPLETED ·Phase: PHASE2
-
Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis
NCT00835874 ·Status: TERMINATED ·Phase: NA
-
Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru
NCT02124122 ·Status: COMPLETED ·Phase: PHASE1
-
Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics
NCT03423589 ·Status: COMPLETED ·Phase: NA
-
Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea
NCT01143272 ·Status: TERMINATED ·Phase: PHASE3
-
Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults
NCT01143623 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Lactobacillus Preparation on the Incidence of Diarrhea
NCT01792739 ·Status: UNKNOWN ·Phase: PHASE4
-
Yogurt Probiotic Bacteria on Relieving Young Children Acute Gastroenteritis
NCT06090708 ·Status: COMPLETED ·Phase: NA
-
Effect and Tolerability of Lactobacillus Rhamnosus GG LA801 for the Preventive Nutritional Care of Nosocomial Diarrhea in Children
NCT04628819 ·Status: TERMINATED ·Phase: NA
-
Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis
NCT04529980 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Probiotics and Antibiotic-Associated Diarrhea
NCT04414722 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effectiveness and Safety of Lactobacillus Acidophilus LA85 in Preventing Antibiotic-Associated Diarrhea
NCT05974657 ·Status: COMPLETED ·Phase: NA
-
Randomized Double-blind Clinical Trial With L.Reuteri Supplementation in Children With Autism Spectrum Disorder
NCT04293783 ·Status: COMPLETED ·Phase: NA
-
Safety of Lactobacillus Reuteri in Healthy Children Aged 2-24 Months
NCT02460575 ·Status: COMPLETED ·Phase: PHASE1